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We determined the antimicrobial susceptibilities of 255 clinical isolates of anaerobic bacteria collected in
2007 and 2008 at a tertiary-care hospital in South Korea. Piperacillin-tazobactam, cefoxitin, imipenem, and
meropenem were highly active -lactam agents against most of the isolates tested. The rates of resistance of
Bacteroides fragilis group organisms and anaerobic Gram-positive cocci to moxifloxacin were 11 to 18% and 0
to 27%, respectively.
Anaerobic bacterial resistance trends may vary greatly, de-
pending on regions or institutions (1). The Clinical and Lab-
oratory Standards Institute (CLSI) does not recommend rou-
tine susceptibility testing of all clinical isolates of anaerobic
bacteria, except for the management of patients with serious
infections (4). A recent survey indicated that only a few labo-
ratories in the United States performed antimicrobial suscep-
tibility testing of anaerobic bacteria due to the complex tech-
niques and predictable susceptibilities involved (5). However,
regional susceptibility patterns are pivotal in the empirical
treatment of infected patients because these patterns are re-
lated to clinical outcomes (13). Therefore, periodic monitoring
of the regional or institutional resistance trends of clinically
important anaerobe isolates is recommended (4). Our investi-
gation of resistance trends of Bacteroides fragilis group organ-
isms from South Korea has been taking place since 1989 (9,
15). However, few studies have focused on the susceptibilities
of other anaerobes. Therefore, the aim of this study was to
determine the recent antimicrobial resistance patterns of fre-
quently isolated anaerobes at a tertiary-care hospital in South
Korea.
Anaerobes were isolated from blood, normally sterile body
fluid, and abscess specimens, but Clostridium difficile was iso-
lated from stool specimens of suspected C. difficile-associated
disease patients at Severance Hospital in 2007 and 2008. The
isolates were identified by either conventional methods (19) or
the ATB 32A system (bioMe´rieux, Marcy l’Etoile, France). A
total of 255 nonduplicated isolates were used in this study,
including 63 of B. fragilis, 57 of other B. fragilis group species,
28 of Prevotella spp., 9 of other Gram-negative bacilli, 15 of
Anaerococcus prevotii, 15 of Peptoniphilus asaccharolyticus, 15
of Finegoldia magna, 13 of Peptostreptococcus spp., 15 of C.
perfringens, 12 of C. difficile, and 13 of other Gram-positive
bacilli.
Antimicrobial susceptibility testing was performed using the
CLSI agar dilution method (4). The medium used was Brucella
agar (Becton Dickinson, Cockeysville, MD) supplemented
with 5 g hemin and 1 g vitamin K1 per ml and 5% laked
sheep blood. The antimicrobial powders used were piperacil-
lin and tazobactam (Yuhan, Seoul, South Korea), cefoxitin
(Merck Sharp & Dohme, West Point, PA), cefotetan (Daii-
chi Pharmaceutical, Tokyo, Japan), clindamycin (Korea Up-
john, Seoul, South Korea), imipenem, metronidazole
(Choong Wae, Seoul, South Korea), chloramphenicol
(Chong Kun Dang, Seoul, South Korea), meropenem (Sumi-
tomo, Tokyo, Japan), moxifloxacin (Bayer Korea, Seoul, South
Korea), and vancomycin (Eli Lilly & Co., Indianapolis, IN). For
the combination of piperacillin and tazobactam, a constant ta-
zobactam concentration of 4 g/ml was added.
An inoculum of 105 CFU was applied with a Steers replica-
tor (Craft Machine Inc., Woodline, PA), and the plates were
incubated in an anaerobic chamber (Forma Scientific, Mari-
etta, OH) for 48 h at 37°C. The MIC of each antimicrobial
agent was defined as the concentration at which there was a
marked reduction in growth, such as from confluent colonies to
a haze, 10 tiny colonies, or 1 to 3 normal-sized colonies. B.
fragilis ATCC 25285 and B. thetaiotaomicron ATCC 29741
were used as controls.
-Lactamase production by anaerobic Gram-negative ba-
cilli, with the exception of B. fragilis group organisms, was
determined by applying test organisms to the Cefinase disks
and recording the results after 30 min (Becton Dickinson,
Cockeysville, MD).
Table 1 shows the MICs of antimicrobial agents and the
resistance rates of the anaerobes tested. Among the 255 iso-
lates, B. fragilis group organisms were the most prevalent
(47%). These organisms are more virulent and more resistant
to antimicrobial agents than most other anaerobes (3). In this
study, piperacillin-tazobactam, cefoxitin, imipenem, and mero-
penem were highly active against B. fragilis group organisms,
with resistance rates of less than 7%. The rates of resistance to
imipenem and piperacillin-tazobactam were 4% and 7%, re-
spectively, for other B. fragilis group organisms. However,
much higher resistance rates were observed for piperacillin (27
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TABLE 1. Antimicrobial activities against 255 anaerobic bacteria isolated in 2007 to 2008
Organism (no. of isolates) and
antimicrobial agent
Breakpoint (g/ml)a MIC (g/ml) Susceptibility (%)a
S I R Range 50% 90% S I R
Bacteroides fragilis (63)
Piperacillin 32 64 128 4–256 8 256 67 6 27
Piperacillin-tazobactam 32 64 128 0.25–128 1 4 97 2 2
Cefoxitin 16 32 64 8–128 16 32 79 16 5
Cefotetan 16 32 64 4–128 8 64 71 14 14
Imipenem 4 8 16 0.06–32 0.125 1 98 0 2
Meropenem 4 8 16 0.06–128 0.125 4 92 5 3
Clindamycin 2 4 8 0.06–128 0.5 128 67 0 33
Moxifloxacin 2 4 8 0.25–128 0.5 8 84 5 11
Chloramphenicol 8 16 32 2–16 4 4 98 2 0
Metronidazole 8 16 32 0.5–8 2 2 100 0 0
B. fragilis group, other species (57)b
Piperacillin 32 64 128 8–256 128 256 42 7 51
Piperacillin-tazobactam 32 64 128 1–128 8 64 89 4 7
Cefoxitin 16 32 64 4–128 32 32 25 68 7
Cefotetan 16 32 64 4–128 128 128 89 5 86
Imipenem 4 8 16 0.13–32 0.5 4 95 2 4
Meropenem 4 8 16 0.13–8 0.25 2 98 2 0
Clindamycin 2 4 8 0.06–128 128 128 16 16 68
Moxifloxacin 2 4 8 0.13–128 2 16 72 10 18
Chloramphenicol 8 16 32 4–16 4 8 98 2 0
Metronidazole 8 16 32 0.5–4 2 2 100 0 0
Prevotella intermedia (10)
Piperacillin 32 64 128 2–16 8 16 100 0 0
Piperacillin-tazobactam 32 64 128 0.03 0.03 0.03 100 0 0
Cefoxitin 16 32 64 0.5–4 2 4 100 0 0
Cefotetan 16 32 64 0.13–16 2 16 100 0 0
Imipenem 4 8 16 0.02–0.06 0.03 0.06 100 0 0
Meropenem 4 8 16 0.03–0.06 0.06 0.06 100 0 0
Clindamycin 2 4 8 0.06–2 0.06 0.06 100 0 0
Moxifloxacin 2 4 8 0.5 0.5 0.5 100 0 0
Chloramphenicol 8 16 32 0.5–1 0.5 1 100 0 0
Metronidazole 8 16 32 0.5–2 0.5 2 100 0 0
Prevotella spp. (18)c
Piperacillin 32 64 128 0.5–256 16 128 78 11 11
Piperacillin-tazobactam 32 64 128 0.03–16 0.03 4 100 0 0
Cefoxitin 16 32 64 0.5–32 1 32 89 11 0
Cefotetan 16 32 64 0.5–64 4 64 72 11 17
Imipenem 4 8 16 0.03–1 0.06 0.5 100 0 0
Meropenem 4 8 16 0.03–1 0.125 0.5 100 0 0
Clindamycin 2 4 8 0.06–128 0.06 128 50 0 50
Moxifloxacin 2 4 8 0.5–16 2 8 56 33 11
Chloramphenicol 8 16 32 0.5–8 4 8 100 0 0
Metronidazole 8 16 32 0.5–8 4 8 100 0 0
Other Gram-negative bacilli (9)d
Piperacillin 32 64 128 0.06–32 NAg NA NA NA NA
Piperacillin-tazobactam 32 64 128 0.03–4 NA NA NA NA NA
Cefoxitin 16 32 64 0.06–8 NA NA NA NA NA
Cefotetan 16 32 64 0.06–8 NA NA NA NA NA
Imipenem 4 8 16 0.02–4 NA NA NA NA NA
Meropenem 4 8 16 0.008–4 NA NA NA NA NA
Clindamycin 2 4 8 0.06–128 NA NA NA NA NA
Moxifloxacin 2 4 8 0.25–128 NA NA NA NA NA
Chloramphenicol 8 16 32 0.13–4 NA NA NA NA NA
Metronidazole 8 16 32 0.13–1 NA NA NA NA NA
Peptostreptococcus spp. (13)e
Piperacillin 32 64 128 0.06–16 0.25 16 100 0 0
Piperacillin-tazobactam 32 64 128 0.03–16 0.25 16 100 0 0
Cefoxitin 16 32 64 0.25–16 1 16 100 0 0
Cefotetan 16 32 64 0.06–128 4 64 62 8 31
Continued on following page
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TABLE 1—Continued
Organism (no. of isolates) and
antimicrobial agent
Breakpoint (g/ml)a MIC (g/ml) Susceptibility (%)a
S I R Range 50% 90% S I R
Imipenem 4 8 16 0.008–4 0.125 2 100 0 0
Meropenem 4 8 16 0.01–4 0.25 4 100 0 0
Clindamycin 2 4 8 0.06–128 0.125 64 77 0 23
Moxifloxacin 2 4 8 0.06–8 0.125 0.25 92 0 8
Chloramphenicol 8 16 32 1–2 2 2 100 0 0
Metronidazole 8 16 32 0.25–1 0.5 1 100 0 0
Anaerococcus prevotii (15)
Piperacillin 32 64 128 0.06–0.5 0.125 0.25 100 0 0
Piperacillin-tazobactam 32 64 128 0.03–1 0.125 0.125 100 0 0
Cefoxitin 16 32 64 0.06–4 0.5 1 100 0 0
Cefotetan 16 32 64 0.06–4 1 2 100 0 0
Imipenem 4 8 16 0.008–0.25 0.06 0.25 100 0 0
Meropenem 4 8 16 0.008–0.25 0.06 0.125 100 0 0
Clindamycin 2 4 8 0.06–128 2 128 60 0 40
Moxifloxacin 2 4 8 0.06–8 0.25 8 87 0 13
Chloramphenicol 8 16 32 1–16 4 8 93 7 0
Metronidazole 8 16 32 0.25–1 1 1 100 0 0
Peptoniphilus asaccharolyticus (15)
Piperacillin 32 64 128 0.06–0.25 0.06 0.06 100 0 0
Piperacillin-tazobactam 32 64 128 0.03–0.25 0.03 0.06 100 0 0
Cefoxitin 16 32 64 0.06–1 0.06 0.5 100 0 0
Cefotetan 16 32 64 0.13–2 0.25 1 100 0 0
Imipenem 4 8 16 0.008–0.13 0.008 0.03 100 0 0
Meropenem 4 8 16 0.008–0.06 0.008 0.03 100 0 0
Clindamycin 2 4 8 0.06–32 0.125 32 67 0 33
Moxifloxacin 2 4 8 0.13–2 0.25 2 100 0 0
Chloramphenicol 8 16 32 1–4 2 4 100 0 0
Metronidazole 8 16 32 0.5–2 1 1 100 0 0
Finegoldia magna (15)
Piperacillin 32 64 128 0.06–0.25 0.06 0.125 100 0 0
Piperacillin-tazobactam 32 64 128 0.03–0.25 0.06 0.125 100 0 0
Cefoxitin 16 32 64 0.06–1 0.5 1 100 0 0
Cefotetan 16 32 64 0.12–4 1 2 100 0 0
Imipenem 4 8 16 0.008–0.13 0.06 0.125 100 0 0
Meropenem 4 8 16 0.03–0.13 0.06 0.125 100 0 0
Clindamycin 2 4 8 0.06–128 0.25 64 73 13 13
Moxifloxacin 2 4 8 0.13–32 0.5 8 60 13 27
Chloramphenicol 8 16 32 2–4 4 4 100 0 0
Metronidazole 8 16 32 0.5–1 0.5 1 100 0 0
Clostridium perfringens (15)
Piperacillin 32 64 128 0.06–0.5 0.25 0.5 100 0 0
Piperacillin-tazobactam 32 64 128 0.03–1 0.25 0.5 100 0 0
Cefoxitin 16 32 64 0.5–2 1 2 100 0 0
Cefotetan 16 32 64 0.06–1 0.25 1 100 0 0
Imipenem 4 8 16 0.03–0.25 0.125 0.125 100 0 0
Meropenem 4 8 16 0.008–0.03 0.015 0.015 100 0 0
Clindamycin 2 4 8 0.06–128 2 4 80 13 7
Moxifloxacin 2 4 8 0.25–16 0.5 0.5 93 0 7
Chloramphenicol 8 16 32 2–8 4 4 100 0 0
Metronidazole 8 16 32 0.02–0.06 0.03 0.06 100 0 0
Vancomycin NA NA NA 0.25–1 0.5 0.5 NA NA NA
Clostridium difficile (12)
Piperacillin 32 64 128 2–8 4 8 100 0 0
Piperacillin-tazobactam 32 64 128 1–16 4 8 100 0 0
Cefoxitin 16 32 64 64–128 64 128 0 0 100
Cefotetan 16 32 64 8–128 8 128 83 0 17
Imipenem 4 8 16 0.25–16 4 8 58 33 8
Meropenem 4 8 16 0.25–2 2 2 100 0 0
Clindamycin 2 4 8 2–128 64 128 8 8 83
Moxifloxacin 2 4 8 1–128 16 32 25 0 75
Chloramphenicol 8 16 32 1–16 4 16 83 17 0
Continued on following page
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to 51%), cefotetan (14 to 68%), and clindamycin (33 to 86%).
These values were similar to those observed in 1997 to 2004 in
the same hospital: piperacillin, 33 to 49%; cefotetan, 14 to
60%; clindamycin, 51 to 76% (15). A higher prevalence of
resistance, in particular to clindamycin, was observed than in
the United States, i.e.,19 to 35% (17). CLSI added a recom-
mendation to test susceptibility to moxifloxacin in 2004 and
2007. In this study, the moxifloxacin resistance rates were 11%
for B. fragilis and 18% for other B. fragilis group organisms.
These rates were slightly higher than the 7 to 9% reported in
Taiwan (11) but lower than those in Greece (14) and the
United States (16 to 75% and 26 to 55%, respectively) (17).
Overall, Prevotella, Porphyromonas, and Fusobacterium iso-
lates are more susceptible than B. fragilis group organisms (7).
Among these organisms, -lactamase producers were resistant
to penicillin and ampicillin (3, 7). A recent study showed that
94% of the Prevotella isolates tested were -lactamase produc-
ers, which correlated well with susceptibility to penicillin (11).
In the present study, -lactamase production was detected in
26 Prevotella isolates (94%) and 1 Fusobacterium isolate (14%).
While 50% of the non-P. intermedia Prevotella isolates were
resistant to clindamycin, all of the P. intermedia isolates were
susceptible to clindamycin. Other studies indicated that 17%
and 36% of the P. intermedia isolates were resistant to clinda-
mycin (8, 16).
Anaerobic Gram-positive cocci account for approximately
one-quarter of all isolates from anaerobic infections. They may
cause various infections, including skin infections, necrotizing
pneumonia, and bacteremia (18). Several species previously
placed in the genus Peptostreptococcus have been reclassified
into new genera, including Anaerococcus, Finegoldia, Micrococ-
cus, and Peptoniphilus (7). These organisms exhibited various
rates of resistance to penicillin, clindamycin, and metronida-
zole (7). A European surveillance study showed that the ma-
jority of the isolates found to be resistant to clindamycin and
penicillin were identified as F. magna (2). In our study, the
rates of resistance of Gram-positive cocci to clindamycin and
moxifloxacin varied according to species. The highest clinda-
mycin resistance observed was 40% of A. prevotii isolates, fol-
lowed by 33% of P. asaccharolyticus isolates. These rates were
much higher than those reported in Europe (4%) and the
United States (8%) (1, 2) but similar to the 25.9% observed in
1994 in South Korea (10). The rates of resistance to moxifloxa-
cin varied from 27% among F. magna isolates to 0% among P.
asaccharolyticus isolates. The difference in resistance rates
among anaerobic Gram-positive cocci may be of importance.
The resistance patterns of these organisms could help in the
selection of appropriate antimicrobial treatment options, al-
though susceptibility testing of individual patient isolates is not
performed.
C. perfringens is generally very susceptible to most antibiotics
(7). The present study showed that all of the antimicrobial
agents tested had high activity against this organism. C. difficile
has highly variable resistance to -lactams, including penicillin,
cephalosporins, imipenem, clindamycin, and moxifloxacin (6,
7). In our study, the rates of resistance to cefoxitin, clindamy-
cin, and moxifloxacin were 100%, 85%, and 77%, respectively.
The C. difficile NAP1/027 epidemic isolates were known to be
resistant to moxifloxacin (12). A high rate of resistance to
moxifloxacin was observed in this study, although none of the
isolates were NAP1/027 strains. Other Gram-positive bacilli,
such as Actinomyces, Bifidobacterium, and Eubacterium species,
are generally susceptible to -lactams, including penicillin.
Metronidazole-resistant isolates were common among these
organisms (3). In our study, 46% of these organisms were
resistant to metronidazole.
In conclusion, piperacillin-tazobactam, cefoxitin, imipenem,
meropenem, metronidazole, and chloramphenicol remain ac-
tive against most anaerobic isolates. The rates of resistance of
Gram-positive cocci to clindamycin and moxifloxacin are vari-
able according to species. The rates of resistance to moxifloxa-
cin are as follows: C. difficile, 75%; anaerobic Gram-positive
TABLE 1—Continued
Organism (no. of isolates) and
antimicrobial agent
Breakpoint (g/ml)a MIC (g/ml) Susceptibility (%)a
S I R Range 50% 90% S I R
Metronidazole 8 16 32 0.5–2 1 1 100 0 0
Vancomycin NA NA NA 0.25–2 0.5 2 NA NA NA
Other Gram-positive bacilli (13)f
Piperacillin 32 64 128 0.06–64 1 8 92 8 0
Piperacillin-tazobactam 32 64 128 0.03–64 0.5 8 92 8 0
Cefoxitin 16 32 64 0.13–32 2 16 92 8 0
Cefotetan 16 32 64 0.13–128 4 64 85 0 15
Imipenem 4 8 16 0.008–2 0.06 0.5 100 0 0
Meropenem 4 8 16 0.008–16 0.125 2 92 0 8
Clindamycin 2 4 8 0.06–128 0.06 128 85 0 15
Moxifloxacin 2 4 8 0.06–4 1 2 92 8 0
Chloramphenicol 8 16 32 1–16 1 2 92 8 0
Metronidazole 8 16 32 0.5–128 16 128 46 8 46
a S, susceptible; I, intermediate; R, resistant.
b Bacteroides thetaiotaomicron (n  25), B. caccae (n  3), B. distasonis (n  9), B. ovatus (n  8), and B. vulgatus (n  12).
c Prevotella bivia (n  10), P. buccae (n  5), and P. oralis (n  3).
d Porphyromonas asaccharolytica (n  2), Fusobacterium varium (n  3), F. necrogenes (n  2), F. nucleatum (n  1), and F. mortiferum (n  1).
e Peptostreptococcus anaerobius (n  9) and P. micros (n  4).
f Acitnomyces odontolyticus (n  3), A. israelii (n  2), A. meyeri (n  1), A. naeslundii (n  1), Bifidobacterium adolescentis (n  3), Bifidobacterium sp. (n  1),
Eubacterium lentum (n  1), and Eubacterium sp. (n  1).
g NA, not available/not applicable.
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cocci, 0 to 27%; B. fragilis group organisms, 11 to 18%. Con-
tinuous monitoring is necessary to detect pattern changes at
regional centers.
This study was supported by a grant from the Korea Healthcare
Technology R&D Project, Ministry for Health, Welfare & Family
Affairs, Republic of Korea (A080504).
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